Oculis Holding AG Warrants is a Swiss biopharmaceutical company that specializes in developing innovative treatments for ophthalmic diseases. With a focus on using novel drug delivery technologies, Oculis aims to provide effective and convenient options for patients suffering from conditions such as dry eye and diabetic macular edema.
